Posted by Michael Wonder on 26 May 2021
Illuminare-1, a novel nerve visualisation investigational fluorophore, granted fast track designation by U.S. FDA
25 May 2021 - Illuminare Biotechnologies announced that its novel nerve imaging agent, Illuminare-1, has been granted fast track designation by the US FDA.
Illuminare-1 is a small molecule, myelin binding agent, the company is developing as a surgical adjunct to improve the visualisation and delineation of critical nerve structures intra-operatively.
